Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 19;17(7):2205–2215. doi: 10.1080/21645515.2020.1855952

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Pfizer Inc. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — Serum bactericidal antibody measurements against serogroup C at 1 month postvaccination in individuals aged ≥2 years administered a single or booster dose of MenACWY-TT, MenC-CRM₁₉₇/Al(OH)_3, MenC-TT, or MenC-CRM₁₉₇/AlPO₄ vaccine.^64–66 (a) Percentage of individuals with rSBA titers ≥1:8, (b) rSBA GMTs, (c) percentage of individuals with hSBA titers ≥1:8, and (d) hSBA GMTs.

*MenC-CRM₁₉₇ vaccine = MenC-CRM₁₉₇/Al(OH)₃ in Knuf 2013⁶⁴ and MenC-CRM₁₉₇/AlPO₄ in Vesikari 2015.⁶⁵ All analyses were performed on ATP immunogenicity cohorts. Knuf 2013: Subjects aged 2–10 years administered a single vaccine dose; MenACWY-TT, n = 293; MenC-CRM₁₉₇/Al(OH)₃, n = 97; blood samples collected at 1 month postvaccination (range, 21–48 days).⁶⁴ Vesikari 2015: Subjects aged 5 years (60–69 months) who had previously received 1 dose of MenACWY-TT or MenC-CRM₁₉₇/AlPO₄ as toddlers were administered a booster dose of the same vaccine. MenACWY-TT, n = 209–215; MenC-CRM₁₉₇/AlPO₄, n = 33–43; blood samples collected at 1 month postbooster (range, 21–48 days).⁶⁵ van Ravenhorst 2017: Subjects aged 10, 12, or 15 years who had previously received a primary dose of MenC-TT as toddlers were administered a booster vaccine dose; MenACWY-TT, n = 78–79; MenC-TT, n = 78–89; blood samples collected at 1 month postbooster (ATP blood sampling window not available).⁶⁶ ATP = according to protocol; GMT = geometric mean titer; hSBA = serum bactericidal antibody using human complement; MenACWY-TT = meningococcal serogroups A, C, W, and Y vaccine conjugated to tetanus toxoid as a carrier protein; MenC-CRM₁₉₇/Al(OH)₃ = meningococcal serogroup C vaccine conjugated to the nontoxic form of diphtheria protein cross-reactive material 197 and adsorbed onto aluminum hydroxide; MenC-CRM₁₉₇/AlPO₄ = meningococcal serogroup C vaccine conjugated to the nontoxic form of diphtheria protein cross-reactive material 197 and adsorbed onto aluminum phosphate; MenC-TT = meningococcal serogroup C vaccine conjugated to tetanus toxoid; rSBA = serum bactericidal antibody using baby rabbit complement.